Female pseudohermaphroditism, not elsewhere classified
ICD-10 Q56.2 is a billable code used to indicate a diagnosis of female pseudohermaphroditism, not elsewhere classified.
Female pseudohermaphroditism is a condition characterized by the presence of female external genitalia in individuals with a male chromosomal pattern (typically 46,XY). This condition arises from various factors, including androgen exposure during fetal development, which can lead to ambiguous genitalia or the development of male characteristics in genetically female individuals. Congenital malformations associated with this condition may include hypospadias, where the urethral opening is located on the underside of the penis, and cryptorchidism, where one or both testes fail to descend into the scrotum. Uterine malformations may also be present, affecting reproductive health. Accurate diagnosis often requires a multidisciplinary approach, including genetic testing and imaging studies to assess the anatomy of the genital tract. The complexity of this condition lies in its varied presentations and the need for thorough clinical evaluation to determine the underlying cause and appropriate management.
Detailed growth and development assessments, including physical examinations and any surgical interventions.
Evaluation of newborns with ambiguous genitalia, management of hypospadias repair, and follow-up for cryptorchidism.
Consideration of psychosocial aspects and parental counseling regarding the condition.
Genetic testing results, family history, and any chromosomal analysis performed.
Genetic counseling for families with a history of intersex conditions and interpretation of karyotype results.
Understanding the implications of genetic findings on management and prognosis.
Used in cases where surgical intervention is required for hypospadias associated with pseudohermaphroditism.
Detailed operative notes and pre-operative assessments.
Pediatric urology may be involved in the surgical management.
Accurate coding of Q56.2 is crucial for appropriate management and treatment planning for patients with female pseudohermaphroditism. It ensures that healthcare providers can track outcomes, allocate resources effectively, and provide necessary support for affected individuals and their families.
